Bloomtechz supplies Arg34-GLP-1(7-37) . In the peptide backbone, nitrogen atoms are mainly found in the amino groups of the amino acids, while oxygen atoms are mostly present in the carboxyl and hydroxyl groups. The various atoms are connected through peptide bonds, assembling into a polypeptide molecule with a specific spatial structure. Bloomtechz uses solid-phase peptide synthesis to produce this product, with precise control over the coupling, cleavage, and purification steps.
High-performance liquid chromatography is used to remove short peptide impurities, strictly controlling product purity and structural integrity, ensuring consistent quality between batches, and meeting research needs like pharmacology studies and in vitro activity tests. Regarding storage and cross-border transport, this peptide is temperature-sensitive and needs to be sealed and kept cold and away from light to avoid peptide chain degradation caused by temperature fluctuations or exposure to light. The packaging uses specialized lyophilization containers, and temperature-controlled packaging is used throughout transport, with proper shock protection.
|
Customized Bottle Caps And Corks:
|
|
Arg34-GLP-1(7-37) COA
 |
||
| Certificate of Analysis | ||
| Compound name | Arg34-GLP-1(7-37) | |
| Grade | Pharmaceutical grade | |
| CAS No. | 204521-68-6 | |
| Quantity | 33g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090055 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.37% |
| Loss on drying | ≤1.0% | 0.21% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.90% |
| Single impurity | <0.8% | 0.62% |
| Total microbial count | ≤750cfu/g | 311 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 725ppm |
| Storage | Store in a sealed, dark, and dry place below 2-8°C | |
|
|
||
Arg34-GLP-1(7-37) is a specifically modified analogue of glucagon like peptide-1. It plays a variety of functions in vivo, especially in the treatment of diabetes and weight control shows potential application value.It usually appears as a white powder, and its solubility is influenced by factors such as solvent type, pH value, and temperature. Under suitable solvents and conditions, it can exhibit good solubility. Having a certain extinction coefficient is an important parameter of its optical properties. The extinction coefficient is related to factors such as peptide concentration, solvent type, and wavelength. By measuring the extinction coefficient, its concentration in solution can be indirectly calculated, and its biological activity or efficacy can be evaluated. It is a kind of polypeptide molecule with specific biological activity, which has potential application value in the field of medicine, especially in the treatment of diabetes. By binding to the glucagon receptor, relevant signaling pathways can be activated to regulate glucose metabolism and insulin secretion.
1. Promote insulin production and secretion
As a type of intestinal insulin hormone, one of its most significant functions is to promote insulin production and secretion. When blood sugar levels rise, it binds to the glucagon receptor, activating adenylate cyclase and increasing intracellular CAMP concentration, thereby enhancing glucose stimulated insulin secretion.
This insulin promoting effect is glucose dependent, that is, when the extracellular glucose concentration reaches a certain value, it can effectively promote insulin secretion. Therefore, it plays an important role in controlling the blood sugar level, especially suitable for adult type 2 diabetes patients.
2. Inhibition of glucagon synthesis and secretion
In addition to promoting insulin secretion, it can also inhibit the synthesis and secretion of glucagon. Glucagon is a hormone that raises blood sugar, which has the opposite effect as insulin. By inhibiting the secretion of glucagon, it helps to maintain stable blood sugar levels and prevent damage to the body caused by high or low blood sugar levels.
3. Delaying gastric emptying and inhibiting intestinal peristalsis
It also has the function of delaying gastric emptying and inhibiting intestinal peristalsis. By slowing down the emptying rate of the stomach, it can lower the peak of postprandial blood sugar and make blood sugar levels more stable. Meanwhile, inhibiting intestinal peristalsis also helps to control feeding, reduce weight, and has certain therapeutic potential for obese patients.
4. Reduce the risk of cardiovascular disease
Research shows that it can also reduce the risk of cardiovascular adverse events in type 2 diabetes patients with cardiovascular disease. This may be related to various mechanisms such as improving blood sugar control and insulin resistance, as well as lowering blood lipids and blood pressure. By comprehensively improving multiple aspects of the cardiovascular system, new treatment strategies have been provided for patients with cardiovascular diseases.
5. Affects tissue metabolism
It can bind to related receptors such as kidneys and skin, affecting tissue metabolism. By interacting with these receptors, it can regulate physiological processes such as energy metabolism, water balance, and electrolyte balance, maintaining the stability of the internal environment of the organism.
Regarding the synthesis of Arg34-GLP-1(7-37), these methods are usually based on principles of biochemistry and molecular biology, and efficient synthesis of target peptides is achieved through different technical means.
1. Gene recombination technology
Gene recombination technology is a method of synthesizing target peptides through genetic manipulation using genetic information from living organisms. In the synthesis of it, gene recombination technology can be achieved through the following steps:
Firstly, isolate genes encoding GLP-1 or its related fragments from suitable organisms or cell lines. Then, these genes are inserted into appropriate expression vectors through gene cloning technology for efficient expression in host cells.
Before gene expression, genes can be modified by techniques such as directed mutagenesis to introduce the required amino acid residues such as Arg34. In this way, when genes are expressed in host cells, they can directly produce GLP-1 fragments with specific modifications.
The expressed protein needs to go through a series of purification steps to remove impurities and improve purity. This usually includes techniques such as cell lysis, centrifugation, and chromatography.
2. Chemical synthesis method
In addition to solid-phase peptide synthesis, there are other chemical synthesis methods available for the synthesis of it. These methods typically involve more complex chemical reactions and steps, but can achieve higher synthesis efficiency and purity.
Fragment condensation method:This method first breaks down GLP-1 or its related fragments into smaller peptide segments, and then synthesizes these peptide segments separately. Finally, these peptide segments are connected through specific chemical reactions to form the complete the product. This method can improve the flexibility and efficiency of synthesis.
Liquid phase synthesis method:Liquid phase synthesis is a method of peptide synthesis in solution. Compared with solid-phase peptide synthesis, liquid-phase synthesis has a higher reaction rate and fewer by-products. However, the purification steps of liquid-phase synthesis are often more complex.
3. Enzymatic synthesis method
Enzymatic synthesis utilizes the catalytic action of enzymes to synthesize peptides. This method has the advantages of mild reaction conditions and fewer by-products. In the synthesis of the product, specific enzymes can be used to catalyze the formation of peptide bonds, thereby achieving efficient synthesis of target peptides.
4. Other biotechnological means
In addition to the above methods, there are also some other biotechnology methods that can be used for the synthesis of Arg34-GLP-1(7-37), such as cell fusion technology, transgenic animal technology, etc. These technologies typically involve more complex biological operations and regulation, but can achieve more efficient synthesis and wider applications.
Comparison of advantages and disadvantages of synthesis methods
The discovery of Arg34-GLP-1(7-37) was built on basic research of Glucagon-Like Peptide-1, with its origins tracing back to the 1980s. In 1986, scientists including Joel Habener and Svetlana Mojsov first identified Glucagon-Like Peptide-1 in the intestine. It is an active fragment produced by the cleavage of proglucagon via prohormone convertases, and one of the two major active forms of Glucagon-Like Peptide-1 in the human body. It was initially found to participate in blood glucose regulation and exert glucose-dependent insulinotropic effects. Earlier, Habener's team had predicted the existence of such glucagon-related peptides through studies on fish proglucagon, laying the foundation for the subsequent discovery of the active fragment.
With in-depth investigations into the physiological functions of Glucagon-Like Peptide-1, scientists found that native Glucagon-Like Peptide-1 is readily hydrolyzed and inactivated by dipeptidyl peptidase-4 (DPP-4) in vivo, with an extremely short half-life, making it difficult to directly apply in research and drug development. In subsequent studies, researchers explored optimization strategies through structural modification. Unexpectedly, they found that replacing lysine (Lys) at position 34 of native Glucagon-Like Peptide-1 with arginine (Arg) yielded the product, which not only retained the original biological activity but also exhibited significantly enhanced receptor agonism. Furthermore, it provided a stable scaffold for further structural modification and half-life extension, becoming a crucial cornerstone in the research and development of Glucagon-Like Peptide-1 receptor agonist drugs, and advancing the progress of related hypoglycemic and anti-obesity medications.
Logistics Control System
Multi-layered constant-temperature protective packaging is Bloomtechz's first line of defense in ensuring the quality of their products during cross-border logistics. The company strictly follows biopharmaceutical peptide transport packaging standards, creating a proprietary packaging solution that is sealed, moisture-proof, temperature-locking, light-resistant, and shock-proof, eliminating quality loss during transportation. The inner layer uses sterile vacuum-sealed light-proof bottles to block air, moisture, and UV rays, preventing peptide powder from oxidizing, absorbing moisture, or denaturing from the start.
The middle layer features a professional bio-cold chain insulation box, filled with high-density polyurethane thermal-locking material, combined with sufficient medical-grade dry ice and gel ice to maintain a constant -20°C low-temperature environment inside the box for a long time, effectively resisting temperature fluctuations during cross-border transport and ensuring the product stays cold throughout. The outer layer uses thickened shockproof and waterproof cardboard, resistant to pressure, wear, and moisture, cushioning bumps, compression, and vibrations during long-distance transport to avoid bottle damage or powder leakage.
All packaging externally displays uniform biopharmaceutical cold chain labels, low-temperature storage instructions, light and moisture warnings, product batch traceability codes, and transport precautions in both Chinese and English, clearly marking temperature control standards, handling guidelines, and storage requirements. Before each batch is shipped, quality control and logistics teams double-check the packaging's sealing, thermal-locking performance, and integrity to ensure there are no defects or risks before dispatch, fully supporting multi-modal cross-border cold chain transport via sea, land, and air.
For vehicle selection and transport route planning, Bloomtechz avoids ordinary logistics channels, using only dedicated biopharmaceutical cold chain transport to build a global low-temperature delivery network. To meet the product's viability needs, the company works exclusively with authorized logistics providers certified for biopharmaceutical cold chain transport and ISO temperature control. All transport vehicles, cold-chain cargo planes, and deep-sea cold chain vessels are equipped with intelligent constant-temperature refrigeration systems, real-time temperature monitoring devices,
and independent light-proof storage compartments, allowing 24/7 precise control and stable low-temperature maintenance, preventing temperature fluctuations. Based on global customer distribution and order requirements, they customize cold chain transport solutions: for long-distance orders to Europe, America, and Australia, priority is given to dedicated deep-sea constant-temperature cold chain shipping lines, with exclusive cold chain compartments on ships controlling temperature,
light, and humidity throughout, avoiding issues of high humidity, large temperature differences, and long transport durations, ensuring peptide activity stays stable;
for urgent research samples or small-scale R&D orders, they use international biopharmaceutical cold chain air transport lines, ensuring fast customs clearance and short-distance delivery to minimize transport time and reduce product exposure risks; for nearby regions like Southeast Asia and East Asia, they use dedicated cross-border constant-temperature cold chain vehicles, providing fully enclosed transport with real-time temperature control, balancing timeliness and quality. All transport personnel are trained and certified in cold chain transport for biological materials, familiar with peptide transport standards and emergency procedures, ensuring transport safety from the ground up.
Frequently Asked Questions
Q1: How do you tightly control trace deamidation impurities in mass production of peptides?
+
-
The Arg34-GLP-1(7-37) peptide has basic amino acid sites prone to minor deamidation side reactions, and conventional lyophilization processes can lead to hidden impurities. Bloomtechz uses gradient chromatography purification and low-temperature vacuum lyophilization, precisely controlling temperature and humidity. This prevents degradation impurities from forming during production, strictly locks in purity and peptide integrity, ensures consistent batch efficacy and activity, and supports the development of high-end peptide drugs.
Q2: Can small-scale and mass production processes be fully identical?
+
-
Yes. Many manufacturers simplify purification steps in small-scale samples, causing deviations when scaled up. Bloomtechz uses a consistent two-step purification system with cation exchange and reversed-phase chromatography for both small and large orders, keeping synthesis, purification, and lyophilization parameters fixed. This prevents differences in activity or impurity profiles between small-scale samples and mass production, enabling seamless process scale-up for customers.
Q3: How do you avoid hidden moisture absorption and activity loss during low-temperature transport?
+
-
This GLP-1 peptide lyophilized powder is highly hygroscopic, and normal cold-chain transport temperature fluctuations can cause condensation, leading to hidden moisture absorption and activity loss. Bloomtechz uses vacuum aluminum foil sealed packaging with dry ice temperature-controlled cold chain, completely isolating moisture and temperature fluctuations, preventing powder clumping and activity loss, ensuring stable product quality upon delivery.
Q4: Is there a quality assurance plan for cross-border cold chain delays?
+
-
Yes, emergency quality guarantees are supported. In the event of customs delays or temporary cold chain holds, our low-temperature sealed packaging can tolerate short-term temperature fluctuations, slowing peptide degradation. In addition, our after-sales team monitors logistics issues throughout, providing quality verification and traceable re-testing services to minimize the risk of product spoilage due to shipping delays.
Q5: How do you avoid the risk of cross-border classification inspections for peptide raw materials?
+
-
These niche active peptides are easily misclassified by customs as restricted biological products. Bloomtechz provides dedicated peptide intermediate classification documents, complete quality testing spectra, and lyophilization process files to clearly define them as chemical research raw materials. This ensures precise compliance in declarations, greatly reduces the likelihood of inspection and detention, and guarantees efficient and stable cross-border delivery.
Hot Tags: arg34-glp-1(7-37) cas 204521-68-6, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Lpamorelin Powder CAS 170851 70 4, Selank Peptide CAS 129954 34 3, Bremelanotide Powder CAS 189691 06 3, DecaPeptide 12 CAS 137665 91 9, Melanotan 2 Powder, Epitalon Powder CAS 307297 39 8